Wayangankar Siddharth A, Patel Bhavin C, Parekh Hiral D, Holter Jennifer L, Lazzara Ralph
aDepartment of Internal Medicine bSection of Hematology and Oncology cSection of Cardiovascular Diseases, University of Oklahoma, Oklahoma City, Oklahoma, USA.
J Cardiovasc Med (Hagerstown). 2015 Jan;16 Suppl 1:S38-41. doi: 10.2459/JCM.0b013e328341d0e5.
Cardiac complications of high-dose cytosine arabinoside (HiDAC), although rare, predominantly include pericarditis, pericardial effusion and cardiomyopathy (with concurrent use of cyclophosphamide). Clinically significant arrhythmias associated with HiDAC, although reported in the literature, are rare. The following case report has for the first time used the Naranjo Scale to document a high-probability association (definite adverse drug reaction) of cytarabine with symptomatic sinus bradycardia.
高剂量阿糖胞苷(HiDAC)的心脏并发症虽然罕见,但主要包括心包炎、心包积液和心肌病(与环磷酰胺联合使用时)。与HiDAC相关的具有临床意义的心律失常虽然在文献中有报道,但很罕见。以下病例报告首次使用了纳兰霍量表来记录阿糖胞苷与症状性窦性心动过缓之间的高概率关联(明确的药物不良反应)。